Difference between revisions of "Team:Northeastern Boston"
| Line 24: | Line 24: | ||
<a id="a-parts"> | <a id="a-parts"> | ||
Parts | Parts | ||
| − | + | <div class='nav-container__arrow'></div> | |
| − | + | </a> | |
</li> | </li> | ||
<div class='sub-nav__children hidden'> | <div class='sub-nav__children hidden'> | ||
| Line 38: | Line 38: | ||
<div class='sub-nav__container'> | <div class='sub-nav__container'> | ||
<li class='sub-nav__parent'> | <li class='sub-nav__parent'> | ||
| − | <a id="a-notebook">Notebook <div class='nav-container__arrow'></div></a> | + | <a id="a-notebook"> |
| + | Notebook | ||
| + | <div class='nav-container__arrow'></div> | ||
| + | </a> | ||
</li> | </li> | ||
<div class='sub-nav__children hidden'> | <div class='sub-nav__children hidden'> | ||
| Line 54: | Line 57: | ||
<div class='sub-nav__container'> | <div class='sub-nav__container'> | ||
<li class='sub-nav__parent'> | <li class='sub-nav__parent'> | ||
| − | <a id="a-humanpractices">Human Practices <div class='nav-container__arrow'></div></a> | + | <a id="a-humanpractices"> |
| + | Human Practices | ||
| + | <div class='nav-container__arrow'></div> | ||
| + | </a> | ||
</li> | </li> | ||
<div class='sub-nav__children hidden'> | <div class='sub-nav__children hidden'> | ||
Revision as of 02:03, 17 September 2015
NORTHEASTERN
"Dr. George D. Yancopoulos, chief scientific officer of Regeneron, said the crisis had pointed up shortcomings in biodefense. “Nobody is really prepared,” he said. “Nobody in the world has rapid response capabilities.”—New York Times, January 2015
Northeastern is working to standardize protein production in microalgae. Chalmydomonas reinhardtii, the workhorse of algae research, is an attractive chassis for several reasons. Its primary carbon source is CO2, it rapidly divides, and it’s a capable of complex post-translational modifications.
Microalgae are relatively inexpensive to scale, yet have all the production capabilities of other Eukaryotic organisms (di-sulfide bonds and glycosylation). This capability could be exploited to treat human disease. For example, there was a shortage of an “antibody-cocktail” during the Ebola outbreak.
